In the first two funding periods, the CRC has focused on the identification of key mechanisms controlling skin homeostasis, regeneration and skin pathology. Key assets were the human skin tissue bank established in Z2 that covered a range of skin diseases and the clinical expertise present, which facilitated close interactions between individual projects and Z2. For the third funding period, a translational skin disease platform Z4 has been implemented, in order to capitalize on these growing translational opportunities. It integrates (immune-) histological expertise and the biobank – that both formerly have been a part of Z2 – into a clinical infrastructure that includes support by a physician scientist and a study nurse to develop diagnostic/prognostic markers and/or therapeutic targets. In order to translate recent findings into clinical studies Z4 also assists in planing trials by coordinating first steps.